daclizumab

ダクリズマブ


Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/09/05 01:24:28」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

English Journal

  • The Use of Biologic Therapies in Uveitis.
  • Schwartzman S1, Schwartzman M2.
  • Clinical reviews in allergy & immunology.Clin Rev Allergy Immunol.2015 Dec;49(3):307-16. doi: 10.1007/s12016-014-8455-6.
  • Therapy for autoimmune ophthalmic disease is currently evolving. The improved understanding of the abnormal immune response in the various forms of uveitis has resulted in targeted therapy. The aberrations of the immune system have been characterized by atypical cell populations, cytokine expression
  • PMID 25431348
  • Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.
  • Bittner S1,2, Wiendl H3.
  • Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.Neurotherapeutics.2015 Nov 12. [Epub ahead of print]
  • Therapeutic options for multiple sclerosis (MS) have significantly increased over the last few years. T lymphocytes are considered to play a central role in initiating and perpetuating the pathological immune response. Currently approved therapies for MS target T lymphocytes, either in an unspecific
  • PMID 26563391
  • Long-Term Immunosuppression After Solitary Islet Transplantation Is Associated With Preserved C-Peptide Secretion for More Than a Decade.
  • Blau JE1, Abegg MR1, Flegel WA2, Zhao X1, Harlan DM3, Rother KI1.
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.Am J Transplant.2015 Nov;15(11):2995-3001. doi: 10.1111/ajt.13383. Epub 2015 Jul 16.
  • We report on two patients with type 1 diabetes (T1D) after solitary islet transplantation in 2001. They received steroid-sparing immunosuppression (daclizumab, sirolimus, and tacrolimus according to the Edmonton protocol). Both patients became insulin independent for 2 years: Patient A, a 42-year-ol
  • PMID 26184712

Japanese Journal

  • 5.小腸移植(<特集>小児藏器移植の現状)
  • 古川 博之,鈴木 友己,藤堂 省
  • 日本外科学会雑誌 111(5), 294-298, 2010-09-01
  • NAID 110007701000
  • イタリアにおける成人小腸単独移植 : 28例29移植の経験から
  • 木村 拓也,Lauro Augusto,Cescon Matteo,Zanfi Chiara,Pinna Antonio Daniele,福澤 正洋
  • 日本消化器外科学会雑誌 41(11), 1883-1891, 2008-11-01
  • … 移植(93%)で,移植の適応としては中心静脈アクセスの確保不能,中心静脈栄養に関連した合併症(繰り返す感染症,肝機能障害)が20例(69%)を占めた.免疫抑制剤はdaclizumab,alemtuzumab,antithymocyte globulinのいずれかをinductionに用い,tacrolimusを維持に用いた.Daclizumab投与例ではプレドニゾロンも併用した.結果:患者/グラフトの5年生存率は74%/71%であった.拒絶反応は13例に認め,全例にステロイドパルス療法を,2例にはOKT3 …
  • NAID 110006980567

Related Links

Daclizumab (trade name Zinbryta) is a therapeutic humanized monoclonal antibody used for the treatment of adults with relapsing forms of multiple sclerosis. Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of ...
Daclizumab is a monoclonal antibody that affects the actions of the body's immune system. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage.



★リンクテーブル★
リンク元mab」「ダクリズマブ

mab」

  [★]

モノクローナル抗体

mab

ダクリズマブ」

  [★]

daclizumab
Zenapax